FUL.L Regulatory News (FUL)

7 Mar 2006 07:01

Fulcrum Pharma PLC07 March 2006 For immediate release 7 March 2006 FULCRUM PHARMA PLC ("Fulcrum" or "the Group" or "the Company") Board Appointment Fulcrum Pharma plc (AIM: FUL), the drug development and strategic outsourcingservices company, is pleased to announce that Angus Bell will join the Board ofFulcrum as a Non-Executive Director with effect from 9th March 2006. Dr Angus Bell, aged 57, has more than thirty years experience in thepharmaceutical industry including a number of strategic and management roles atQuintiles and Glaxo. At Quintiles, the global leader in pharmaceutical services, Dr Bell was ChiefOperating Officer for Preclinical Services and General Manager of EarlyDevelopment and Laboratory Services at their Edinburgh facility. Additionallyhe established an early development consultancy service within the company. Earlier in his career Dr Bell worked at Glaxo where he made significantcontributions to the design and development of several marketed medicines(Zantac(TM), Imigran(TM), Zofran(TM) and Serevent(TM)).After the formation of Glaxo Wellcome, Dr Bell led a programme to re-design thekey business processes of R&D including drug candidate selection, clinicaldevelopment, and new product delivery. Currently Dr Bell is a Non-Executive Director of Pharmaceutical Profiles Ltd, aunique phase I clinical CRO offering improved decision making in early clinicaldevelopment. In 2005, following the MBO of the company from its founders, DrBell acted as interim CEO. He also serves as Non-Executive Director of MaccinePty Ltd., a Singapore-based preclinical services company. Jon Court, Chief Executive of Fulcrum Pharma, said: "I am delighted towelcome Angus to the Board. Angus brings a wealth of experience to Fulcrumparticularly in the preclinical arena. Recently Fulcrum announced that itplanned to strengthen the Board with additional expertise from the servicesector. We feel that Angus' experience, in particular that gained fromhis various roles at Quintiles, will be instrumental in helping Fulcrum drivethe Company's global service model further forward and maximise theexciting opportunities that lie ahead." Angus Bell said: "Fulcrum offers a unique approach to global servicesaround drug development. I am very excited about joining the Board and applyingmy knowledge and expertise to Fulcrum's business strategy and coreoperations." Fulcrum confirms that, save for the above, there are no other matters underparagraph (g) of Schedule 2 of the AIM rules to be announced. For further information, please contact: Fulcrum Pharma PLC Tel: 0870 710 7152Jon Court, Chief Executive Buchanan Communications Tel: 020 7466 5000Mary-Jane Johnson Notes for editors About Fulcrum Pharma plc Fulcrum Pharma plc is an independent, drug development company that is the firstto offer global virtual drug development and strategic outsourcing services tothe pharmaceutical industry. The Group has expertise in the design, executionand delivery of drug development programmes and relies on state of the artinformation technology and infrastructure in the supply of its services. Through Fulcrum's services to its clients, the Directors believe thatthere is the capacity to deliver products faster and more efficiently to theglobal pharmaceutical market. Fulcrum does this by using its skills in thedesign of drug programmes that deliver the necessary information fordecision-making and product registration. In so doing, Fulcrum works closelywith its clients to meet their strategic R&D goals. Fulcrum Pharma is listed on the Alternative Investment Market of the LondonStock Exchange having successfully floated in March 2000. This information is provided by RNS The company news service from the London Stock Exchange